HIS study describes the clinical profile of tacrolimus (Tac) nephrotoxicity after renal transplantation. Tac was given initially as a 0,075 to 0.1 mg/kg/day IV continuous infusion and then orally at 0.15 mglkg twice daily. Patients were selected based on a rising serum creatinine. normal ultrasound, and absence of rejection on biopsy, leading to a reduction in Tac dosage and fall in creatinine. Twenty-two (17%) cases of nephrotoxicity were identified among 128 kidney transplant biopsies. This compares with a 20.5<J~ incidence reported by the Japanese FK506 study group.! The onset of nephrotoxicity occurred 1 to 156 weeks postoperatively. The mean baseline creatinine was 2.4 ::': 1.9 mg/dL (range 1.0 to 9.9) and rose 40.6% ::': 14.2% (range 11 to 66) during episodes of nephrotoxicity. Mean peak plasma (n = 10) and whole blood (n = 12) Tac levels during the toxic episodes were. respectively, 2.7 ::' : 0.8 ng/mL (range 1.1 to 3.5) and 31.6 ::': 10.6 ng/mL (range 14.5 to 50.5). The drug levels were considered to be beyond the therapeutic range in 18 of 22 (82%) 1(0) fall in serum creatinine in 1 to 14 days. Serum potassium higher than 5.0 mEq/L was recorded in 9 of 22 (41 %) cases. More than three elevations in blood glucose greater than 140 mg/dL were recorded in 4 of II (36%) non-diabetic patients. Hand tremors were seen in two (9%) cases and elevated diastolic blood pressure higher than 90 mm Hg in seven (32%) patients.
